CYTK / Cytokinetics, Incorporated - SEC-Einreichungen, Jahresbericht, Proxy Statement

Table 1: Newly Registered Securities

Calculation of Filing Fee Tables S-8 CYTOKINETICS INC Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, $0.

FORM 8-K Item 5.07 Submission of Matters to a Vote of Security Holders.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2026 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission

As filed with the Securities and Exchange Commission on May 27, 2026

S-8 As filed with the Securities and Exchange Commission on May 27, 2026 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2026 Cytokinetics, Incorpo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2026 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission

Cytokinetics, Incorporated 9,859,155 Shares of Common Stock Underwriting Agreement

EX-1.1 Exhibit 1.1 Cytokinetics, Incorporated 9,859,155 Shares of Common Stock Underwriting Agreement May 6, 2026 Morgan Stanley & Co. LLC 1585 Broadway  New York, New York 10036 Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 J.P. Morgan Securities LLC 270 Park Avenue New York, New York 10017 Jefferies LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Cytokine

9,859,155 shares Common stock

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-285376 PROSPECTUS SUPPLEMENT (To prospectus dated February 27, 2025) 9,859,155 shares Common stock We are offering 9,859,155 shares of our common stock pursuant to this prospectus supplement and the accompanying prospectus. Our common stock is listed on the Nasdaq Global Select Market under the trading symbol “CYTK.” On

Security Type

Calculation of Filing Fee Tables S-3 CYTOKINETICS INC Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid 1 Equity Common stock, par value $0.

Glossary of Terms

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0

FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 05, 2026 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission

$650,000,000 Common stock

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-285376 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanyin

Forward-Looking Statements This presentation contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking stateme

EX-99.1 Exhibit 99.1 1 Forward-Looking Statements This presentation contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's safe harbor for forward-looking statements. Examples of such statements include, but

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2026 Cytokinetics, Incorpo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2026 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission

Cytokinetics Reports First Quarter 2026 Financial Results and Provides Business Update U.S. Launch of MYQORZO® (aficamten) in Late January Met with Strong Demand; Over 275 HCPs Prescribed MYQORZO to an estimated 680 Patients in Q1 ACACIA-HCM Met Dual

Cytokinetics Reports First Quarter 2026 Financial Results and Provides Business Update U.

SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

TABLE OF CONTENTS SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934         Filed by the Registrant ☒     Filed by a Party other than the Registrant  ☐         Check the appropriate box:          ☐     Preliminary Proxy Statement  ☐     Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒     Definitive Proxy Statement  ☐     Definitive Additional Materials  ☐     Soliciting Material under § 240.

ARS

MEETING THE MOMENT ANNUAL REPORT 2025Research Drug Candidate $ȴFDPWHQ $ȴFDPWHQ $ȴFDPWHQ 8ODFDPWHQ 2PHFDPWLY 0HFDUELO Research CK-089 Therapeutic Area oHCM Approved in U.

AMENDMENT NO. 1 TO THE COLLABORATION AND LICENSE AGREEMENT

Exhibit 10.23 [ * ] – CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, ITEM 601(B)(10). SUCH EXCLUDED INFORMATION IS NOT MATERIAL AND OF THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT NO. 1 TO THE COLLABORATION AND LICENSE AGREEMENT This Amendment Agreement this (“Amendment Agreement”) is entered into as of December 15, 2025 (the “Amendm

Table 1: Newly Registered Securities

Calculation of Filing Fee Tables S-8 CYTOKINETICS INC Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock $0.

INDEX Glossary of Terms FORWARD LOOKING STATEMENTS PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PART I PART II PART III PART IV EXHIBIT INDEX SIGNATURES

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 From the transition period from to Commission file number: 000-5

As filed with the Securities and Exchange Commission on February 26, 2026

S-8 As filed with the Securities and Exchange Commission on February 26, 2026 Registration No.

DESCRIPTION OF DIRECTOR COMPENSATION

Exhibit 10.34 DESCRIPTION OF DIRECTOR COMPENSATION Our non-employee director compensation program consists of both a cash component and an equity component. Non-employee directors are also able to elect to receive their annual base retainers in equity, as further described below. We do not compensate members of the Board of Directors or committees on a per-meeting basis. Annual Retainers Our non-e

CYTOKINETICS, INCORPORATED AMENDED AND RESTATED 2004 EQUITY INCENTIVE PLAN AMENDED BY THE BOARD OF DIRECTORS: FEBRUARY 6, 2013 APPROVED BY STOCKHOLDERS: MAY 22, 2013 AMENDED TO REFLECT THE REVERSE STOCK SPLIT: JUNE 25, 2013 AMENDED AND RESTATED BY TH

Exhibit 10.11+ CYTOKINETICS, INCORPORATED AMENDED AND RESTATED 2004 EQUITY INCENTIVE PLAN AMENDED BY THE BOARD OF DIRECTORS: FEBRUARY 6, 2013 APPROVED BY STOCKHOLDERS: MAY 22, 2013 AMENDED TO REFLECT THE REVERSE STOCK SPLIT: JUNE 25, 2013 AMENDED AND RESTATED BY THE BOARD OF DIRECTORS: FEBRUARY 3, 2015 APPROVED BY STOCKHOLDERS: MAY 20, 2015 AMENDED AND RESTATED BY THE BOARD OF DIRECTORS: FEBRUARY

FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2026 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commi

Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update MYQORZO® Approved for Adults with Symptomatic Obstructive HCM in U.S., China and Europe; U.S. Launch Underway with First Prescriptions Dispensed within Days of Dr

Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update MYQORZO® Approved for Adults with Symptomatic Obstructive HCM in U.

FORM 8-K Item 8.01 Other Events.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2026 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commi

FORM 8-K Item 8.01 Other Events.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2025 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commi

FORM 8-K Item 8.01 Other Events.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2025 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commi

FORM 8-K Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2025 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commi

Glossary of Terms

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe

FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 05, 2025 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commi

CYTOKINETICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Interactions with FDA Progressing Towards December 26, 2025 PDUFA Date for Aficamten; U.S. Commercial Launch Preparations on Track Ex-U.S. Regulatory Reviews of Af

CYTOKINETICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Interactions with FDA Progressing Towards December 26, 2025 PDUFA Date for Aficamten; U.

144

144 0001522780 XXXXXXXX LIVE 0001061983 CYTOKINETICS INCORPORATED 000-50633 350 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 6506243000 EDWARD KAYE Director Common Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004 6757 384946.

144

144 0001288859 XXXXXXXX LIVE 0001061983 CYTOKINETICS, INCORPORATED 000-50633 350 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 6506243000 ROBERT BLUM Director Officer Common Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004 15000 824400.

144

144 0001522780 XXXXXXXX LIVE 0001061983 CYTOKINETICS, INCORPORATED 000-50633 350 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 6506243000 EDWARD KAYE Director Common Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004 6695 360793.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): September 16, 2025 Cytokinetics,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): September 16, 2025 Cytokinetics, Incorporated (Exact Name of Registrant as Specified in Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commissi

1

EX-99.2 Exhibit 99.2 NEWS RELEASE Cytokinetics Announces Pricing of Upsized $650.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2027 Convertible Notes 2025-09-16 SOUTH SAN FRANCISCO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE)-Cytokinetics, Incorporated (“Cytokinetics”) (Nasdaq: CYTK) today announced the pricing of its offering of $650.0 million aggregate principal amount of 1.75

1

EX-99.1 Exhibit 99.1 NEWS RELEASE Cytokinetics Announces Proposed Private Placement of $550.0 Million of Convertible Senior Notes 2025-09-16 SOUTH SAN FRANCISCO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (“Cytokinetics”) (Nasdaq: CYTK) today announced its intention to offer, subject to market conditions and other factors, $550.0 million aggregate principal amount of conv

CYTOKINETICS, INCORPORATED U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION as Trustee Dated as of September 19, 2025 1.75% Convertible Senior Notes due 2031

EX-4.1 Exhibit 4.1 CYTOKINETICS, INCORPORATED and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION as Trustee INDENTURE Dated as of September 19, 2025 1.75% Convertible Senior Notes due 2031 TABLE OF CONTENTS Page Article 1. Definitions; Rules of Construction 1 Section 1.01. Definitions 1 Section 1.02. Other Definitions 13 Section 1.03. Rules of Construction 14 Article 2. The Notes 14 Section 2.01. F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): September 15, 2025 Cytokinetics,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): September 15, 2025 Cytokinetics, Incorporated (Exact Name of Registrant as Specified in Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commissi

FORM 8-K/A Item 8.01 Other Events. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2025 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commi

CYTOKINETICS PRESENTS NEW DATA RELATED TO AFICAMTEN AT THE EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2025 Additional Data from MAPLE-HCM Shows Aficamten Improves Cardiac Structure and Function Compared to Metoprolol; Simultaneous Publication in the Jou

CYTOKINETICS PRESENTS NEW DATA RELATED TO AFICAMTEN AT THE EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2025 Additional Data from MAPLE-HCM Shows Aficamten Improves Cardiac Structure and Function Compared to Metoprolol; Simultaneous Publication in the Journal of the American College of Cardiology New Analysis Shows Annual Incidence Rate of Atrial Fibrillation with Aficamten is 1.

CYTOKINETICS PRESENTS NEW DATA RELATED TO AFICAMTEN AT THE EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2025 Additional Data from MAPLE-HCM Shows Aficamten Improves Cardiac Structure and Function Compared to Metoprolol; Simultaneous Publication in the Jou

CYTOKINETICS PRESENTS NEW DATA RELATED TO AFICAMTEN AT THE EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2025 Additional Data from MAPLE-HCM Shows Aficamten Improves Cardiac Structure and Function Compared to Metoprolol; Simultaneous Publication in the Journal of the American College of Cardiology New Analysis Shows Annual Incidence Rate of Atrial Fibrillation with Aficamten is 1.

FORM 8-K Item 8.01 Other Events. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2025 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commiss

CYTOKINETICS ANNOUNCES PRIMARY RESULTS FROM MAPLE-HCM PRESENTED AT THE EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2025 AND PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE Positive Trial Demonstrates Superiority of Aficamten to Standard-of-Care Beta-Blo

CYTOKINETICS ANNOUNCES PRIMARY RESULTS FROM MAPLE-HCM PRESENTED AT THE EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2025 AND PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE Positive Trial Demonstrates Superiority of Aficamten to Standard-of-Care Beta-Blocker Metoprolol Primary Endpoint Result Consistent Across All Prespecified Subgroups Company to Host Investor Event and Webcast Tuesday September 2, 2025, at 8:00 AM Eastern Time SOUTH SAN FRANCISCO, Calif.

144

144 0001923988 XXXXXXXX LIVE 0001061983 CYTOKINETICS, INCORPORATED 000-50633 350 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 6506243000 ROBERT HARRINGTON Director Common Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004 4300 151919.

144

144 0001522780 XXXXXXXX LIVE 0001061983 CYTOKINETICS INC 000-50633 350 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 6506243000 EDWARD KAYE Director Common Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004 6756 238689.

FORM 8-K Item 8.01 Other Events. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2025 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commiss

FORM 8-K Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2025 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commiss

LETTER

August 13, 2025 Sung Lee Executive Vice President and Chief Financial Officer Cytokinetics, Inc.

* * * * *

CORRESP August 8, 2025 Via EDGAR Division of Corporation Finance Office of Life Sciences U.

Certificate of Amendment of Amended and Restated Certificate of Incorporation

Exhibit 3.6 CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CYTOKINETICS, INCORPORATED CYTOKINETICS, INCORPORATED, a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies that: FIRST: The name of the corporation is CYTOKINETICS, INCORPORATED. SECOND: The date on which the Ce

CYTOKINETICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Regulatory Reviews of Aficamten for Obstructive HCM Progressing in U.S., E.U. and China; Late-Cycle Meeting with U.S. FDA Scheduled for September Ahead of Decembe

CYTOKINETICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Regulatory Reviews of Aficamten for Obstructive HCM Progressing in U.

Glossary of Terms

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) CYTOKINETICS, INCORPORATED (Exact name of Registrant as specified in its charter) Table 1: Newly Registered Securities Security Type  Security Class Title  Fee   Calculation   Rule   Amount  to be   Registered(1)  Proposed  Maximum  Offering  Price Per  Share  Proposed  Aggregate  Maximum  Offering  Price  Fee Rate  Amount of  Registration  Fee  Equity  Common Stock $0.

FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 07, 2025 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commiss

As filed with the Securities and Exchange Commission on August 7, 2025

S-8 As filed with the Securities and Exchange Commission on August 7, 2025 Registration No.

Certificate of Amendment of Amended and Restated Certificate of Incorporation

EX-4.7 Exhibit 4.7 CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CYTOKINETICS, INCORPORATED CYTOKINETICS, INCORPORATED, a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies that: FIRST: The name of the corporation is CYTOKINETICS, INCORPORATED. SECOND: The date on which

LETTER

July 29, 2025 Sung Lee Executive Vice President and Chief Financial Officer Cytokinetics, Inc.

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission

Glossary of Terms

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0

FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 06, 2025 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission

CYTOKINETICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE PDUFA Date for Aficamten in Obstructive HCM Extended by FDA to December 26, 2025 Topline Results from MAPLE-HCM Expected in May Enrollment Completed in ACACIA-HCM;

CYTOKINETICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE PDUFA Date for Aficamten in Obstructive HCM Extended by FDA to December 26, 2025 Topline Results from MAPLE-HCM Expected in May Enrollment Completed in ACACIA-HCM; Topline Results Expected in 1H 2026 ~$1.

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2025 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commissi

ARS

VISION IN MOTION ANNUAL REPORT 20247REHWKHbOHDGLQJPXVFOHIRFXVHG VSHFLDOW\ELRSKDUPDFRPSDQ\ LQWHQWRQPHDQLQJIXOO\LPSURYLQJ WKHOLYHVRISDWLHQWV WKURXJK JOREDODFFHVVWRRXU LQQRYDWLYHPHGLFLQHV VISION2030 Empowering Muscle, Empowering Lives INNO OVATION N Advance 2 approved products across 3 indications and 10 NMEs in our pipeline IGNIT TION Achieve broad access and rapid use of our

SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

TABLE OF CONTENTS SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934         Filed by the Registrant ☒     Filed by a Party other than the Registrant  ☐         Check the appropriate box:          ☐     Preliminary Proxy Statement  ☐     Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒     Definitive Proxy Statement  ☐     Definitive Additional Materials  ☐     Soliciting Material under § 240.

SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

TABLE OF CONTENTS SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934         Filed by the Registrant ☒     Filed by a Party other than the Registrant  ☐         Check the appropriate box:         ☒     Preliminary Proxy Statement  ☐     Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))  ☐     Definitive Proxy Statement  ☐     Definitive Additional Materials  ☐     Soliciting Material under § 240.

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2025 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commissi

Description of Director Compensation

Exhibit 10.33 DESCRIPTION OF DIRECTOR COMPENSATION Our non-employee director compensation program consists of both a cash component and an equity component. Non-employee directors are also able to elect to receive their annual base retainers in equity, as further described below. We do not compensate members of the Board of Directors or committees on a per-meeting basis. Annual Retainers Our non-e

Form of Common Stock Warrant Agreement and Warrant Certificate.

Exhibit 4.9 CYTOKINETICS, INCORPORATED AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF CYTOKINETICS, INCORPORATED FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between CYTOKINETICS, INCORPORATED a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and exi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commi

License and Collaboration Agreement, dated November 18, 2024, by and between the Company and Bayer Consumer Care AG

Exhibit 10.22 [ * ] – CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, ITEM 601(B)(10). SUCH EXCLUDED INFORMATION IS NOT MATERIAL AND OF THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Confidential Execution Version COLLABORATION AND LICENSE AGREEMENT This Collaboration and License Agreement (this “Agreement”) is entered into as of November 18, 202

CYTOKINETICS REPORTS FOURTH QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Commercial Launch Preparations Advancing Prior to September 26 PDUFA Date; Regulatory Filings Under Review in U.S., Europe and China Topline Results from MAPLE-HC

Exhibit 99.1 CYTOKINETICS REPORTS FOURTH QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Commercial Launch Preparations Advancing Prior to September 26 PDUFA Date; Regulatory Filings Under Review in U.S., Europe and China Topline Results from MAPLE-HCM Expected in Q2 2025 Company Provides 2025 Financial Guidance; ~$1.2 Billion in Cash, Cash Equivalents and Investments as of December 31

As filed with the Securities and Exchange Commission on February 27, 2025

S-3ASR 1 d778918ds3asr.htm S-3ASR As filed with the Securities and Exchange Commission on February 27, 2025 Registration No. 333-     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Cytokinetics, Incorporated (Exact name of registrant as specified in its charter) Delaware 94-3291317 (State or other jurisdictio

Form of Debt Securities Warrant Agreement and Warrant Certificate.

Exhibit 4.11 CYTOKINETICS, INCORPORATED AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF CYTOKINETICS, INCORPORATED FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between CYTOKINETICS, INCORPORATED, a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organi

Incentive Compensation Recoupment Policy

EXHIBIT 97.1 Cytokinetics, Incorporated Incentive Compensation Recoupment Policy 1. Introduction The Board of Directors (the “Board”) of Cytokinetics, Incorporated, a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this “Policy”) providing for the Company’s recoupment o

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Cytokinetics, Incorporated (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate(4) Amount of Registration Fee(4) Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Common Stock, $0.

Form of Preferred Stock Warrant Agreement and Warrant Certificate.

Exhibit 4.10 CYTOKINETICS, INCORPORATED AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF CYTOKINETICS, INCORPORATED FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between CYTOKINETICS, INCORPORATED a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organiz

Open Market Sale AgreementSM, dated February 27, 2025 by and between Cytokinetics, Incorporated and Jefferies LLC.

Exhibit 1.2 OPEN MARKET SALE AGREEMENTSM February 27, 2025 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Cytokinetics, Incorporated, a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s co

Amendment to License and Collaboration Agreement, dated December 17, 2024, by and between the Company and Genzyme Corporation (as assignee of Corxel Pharmaceuticals Limited (f/k/a Ji Xing Pharmaceuticals Limited))

EXHIBIT 10.21 [ * ] – CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, ITEM 601(B)(10). SUCH EXCLUDED INFORMATION IS NOT MATERIAL AND OF THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Amendment to License and Collaboration Agreement This AMENDMENT TO LICENSE AND COLLABORATION AGREEMENT (this “Amendment”), dated as of December 17, 2024, is entered

Form of Indenture.

Exhibit 4.7 CYTOKINETICS, INCORPORATED AND , AS TRUSTEE FORM OF INDENTURE DATED AS OF Debt Securities CYTOKINETICS, INCORPORATED FORM OF INDENTURE THIS INDENTURE, dated as of [•], between CYTOKINETICS, INCORPORATED, a Delaware corporation (the “Company”), and [TRUSTEE], as trustee (the “Trustee”): WHEREAS, for its lawful corporate purposes, the Company has duly authorized the execution and deliver

Form 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 From the transition period from to Commission file number: 000-5

Insider Trading Policies and Procedures

EXHIBIT 19.1 CYTOKINETICS, INCORPORATED STOCK TRADING POLICY Effective as of January 2, 2025 1. PURPOSE In an effort to comply with federal and state securities laws governing (a) trading in Cytokinetics, Incorporated (the “Company”) securities while in the possession of “material nonpublic information” concerning the Company, and (b) tipping or disclosing material nonpublic information to outside

EX-99

EX-99 2 exhibit99.txt Exhibit 99 Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Institutional Asset Management Trust Company BK Fidelity Management

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2025 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2024 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2024 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commi

CYTK / Cytokinetics, Incorporated / T. Rowe Price Investment Management, Inc. Passive Investment

SC 13G 1 cytk13gsep24.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) CYTOKINETICS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 23282W605 (CUSIP NUMBER) September 30, 2024 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant

CYTK / Cytokinetics, Incorporated / BlackRock, Inc. Passive Investment

SC 13G/A 1 us23282w6057111224.txt us23282w6057111224.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 6) CYTOKINETICS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 23282W605 - (CUSIP Number) September 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box

CYTK / Cytokinetics, Incorporated / VANGUARD GROUP INC Passive Investment

SC 13G/A 1 UnitedStates13GCytokineti.txt 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 9)* (Name of Issuer) Cytokinetics Inc (Title of Class of Securiti

CYTK / Cytokinetics, Incorporated / FMR LLC Passive Investment

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.4 CYTOKINETICS INC COMMON STOCK Cusip #23282W605 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #23282W605 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 12,216,482 Item 6: 0 Item 7: 12,415,642 Item 8: 0 Item 9:

Sixth Amendment to Lease, dated July 30, 2024, by and between KR Oyster Point 1, LLC, and Cytokinetics, Incorporated

Exhibit 10.2 SIXTH AMENDMENT TO LEASE This SIXTH AMENDMENT TO LEASE ("Sixth Amendment") is made and entered into as of July 30, 2024 (the "Effective Date"), by and between KR OYSTER POINT I, LLC, a Delaware limited liability company ("Landlord"), and CYTOKINETICS INCORPORATED, a Delaware corporation ("Tenant"). r e c i t a l s : A. Landlord and Tenant are parties to the Lease dated July 24, 2019 (

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 01, 2024 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commi

Employment Offer Letter between Cytokinetics, Incorporated and Brett Pletcher

Exhibit 10.1 August 13, 2024 Brett Pletcher 442 Serenity Point Drive Henderson, NV 89012 Dear Brett, I am pleased to offer you a position with Cytokinetics, Inc. (the "Company"), as EVP, Chief Legal Officer, in the Legal Department. In this role, you will be a remote employee performing services at your usual residence at Henderson, Nevada and report directly to Robert Blum, Chief Executive Office

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe

CYTK / Cytokinetics, Incorporated / VANGUARD GROUP INC Passive Investment

SC 13G/A 1 UnitedStates13GCytokineti.txt 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 8)* (Name of Issuer) Cytokinetics Inc (Title of Class of Securiti

CYTK / Cytokinetics, Incorporated / BlackRock, Inc. Passive Investment

SC 13G/A 1 us23282w6057102324.txt us23282w6057102324.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 6) CYTOKINETICS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 23282W605 - (CUSIP Number) September 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commiss

Employment Offer Letter between Cytokinetics, Incorporated and Sung H. Lee

Exhibit 10.1 March 28, 2024 Sung H. Lee 2121 Webster St. #509 San Francisco, CA 94115 Dear Sung, I am pleased to offer you a position with Cytokinetics, Inc. (the "Company"), as EVP, Chief Financial Officer, in the Accounting & Finance Department. In this role, you will report directly to Robert Blum, Chief Executive Officer. This offer is contingent, however, on the items listed on the second pag

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-50633 CYTOKINETI

CK-586 Revenue Participation Right Purchase Agreement, dated May 22, 2024, by and between Royalty Pharma Investments 2019 ICAV and the Company

Exhibit 10.6 [ * ] – CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, iTEM 601(B)(10). sUCH EXCLUDED INFORMATION IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. CK-586 Revenue Participation Right Purchase Agreement By and Between Cytokinetics, Incorporated and Royalty Pharma Investments 2019 ICAV Dated as of May 22,

Agreement, dated January 7, 2022, by and between the Company and Royalty Pharma Investments 2019 ICAV

Exhibit 10.4 [ * ] – CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, iTEM 601(B)(10). sUCH EXCLUDED INFORMATION IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. AMENDMENT NO. 1 TO REVENUE PARTICIPATION RIGHT PURCHASE AGREEMENT This Amendment No. 1 To Revenue Participation Right Purchase Agreement, dated as of May 22

Common Stock Option and Purchase Agreement, dated May 22, 2024, by and between Royalty Pharma Investments 2019 ICAV and the Company

Exhibit 10.7 CYTOKINETICS, INCORPORATED COMMON STOCK OPTION PURCHASE AGREEMENT THIS COMMON STOCK OPTION AND PURCHASE AGREEMENT (the “Agreement”) is made as of May 22, 2024 (the “Execution Date”) by and between Cytokinetics, Incorporated, a Delaware corporation (the “Company”), and Royalty Pharma Investments 2019 ICAV, an Irish collective asset-management vehicle (the “Investor”). Capitalized terms

Third Amendment, dated May 22, 2024, to Development Funding Loan Agreement, dated January 7, 2022, by and among Royalty Pharma Development Funding, LLC and the Company

Exhibit 10.3 [ * ] – CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, iTEM 601(B)(10). sUCH EXCLUDED INFORMATION IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. THIRD AMENDMENT AND CONSENT This THIRD AMENDMENT AND CONSENT (this “Third Amendment”), effective as of May 22, 2024 (the “Third Amendment Effective Date”),

2024 Development Funding Loan Agreement, dated May 22, 2024, by and among Royalty Pharma Development Funding, LLC and the Company

Exhibit 10.5 [ * ] – CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, iTEM 601(B)(10). sUCH EXCLUDED INFORMATION IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. 2024 DEVELOPMENT FUNDING LOAN AGREEMENT THIS 2024 DEVELOPMENT FUNDING LOAN AGREEMENT (as the same may from time to time be amended, modified, supplemented o

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 08, 2024 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commiss

CYTOKINETICS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS Type B Meeting Held with FDA Related to Potential Risk Mitigation Strategies for Aficamten; Company Has Initiated Rolling NDA Submission FDA Cleared Protocol Amendment for FOREST-HCM Reducing

CYTOKINETICS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS Type B Meeting Held with FDA Related to Potential Risk Mitigation Strategies for Aficamten; Company Has Initiated Rolling NDA Submission FDA Cleared Protocol Amendment for FOREST-HCM Reducing Frequency of Echocardiographic Monitoring Required During Maintenance Treatment ~$1.

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): June 7, 2024 Cytokinetics, Incorporated (Exact Name of Registrant as Specified in Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 05, 2024 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commissio

As we had previously stated, throughout 2023, Cytokinetics engaged in Business Development discussions with potential strategic partners with respect to

Exhibit 99.1 As we had previously stated, throughout 2023, Cytokinetics engaged in Business Development discussions with potential strategic partners with respect to aficamten. Leading up to and after our late December 2023 disclosure of top-line results from SEQUOIA-HCM, the Phase 3 clinical trial of aficamten, Cytokinetics was approached by one of the third parties with whom we had previously en

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) CYTOKINETICS, INCORPORATED (Exact name of Registrant as specified in its charter) Table 1: Newly Registered Securities Security Type  Title of Securities  to be Registered  Fee   Calculation   Rule   Amount  to be   Registered(1)  Proposed  Maximum  Offering  Price Per  Share  Proposed  Maximum  Aggregate  Offering  Price  Fee Rate  Amount of  Registration  Fee  Equity  Common Stock $0.

As filed with the Securities and Exchange Commission on June 3, 2024

As filed with the Securities and Exchange Commission on June 3, 2024 Registration No.

Underwriting Agreement, dated as of May 22, 2024, by and among Cytokinetics, Incorporated, J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and Morgan Stanley & Co. LLC.

Exhibit 1.1 Cytokinetics, Incorporated 9,803,922 Shares of Common Stock Underwriting Agreement May 22, 2024 J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10017 Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 Ladies and Gentlemen: Cytokinetics, Incorporated, a Delaware corporation (the “Company”), pr

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 28, 2024 Cytokinetics, Incorporated (Exact Name of Registrant as Specified in Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission Fil

9,803,922 shares Common stock

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-268483 PROSPECTUS SUPPLEMENT (To prospectus dated November 18, 2022) 9,803,922 shares Common stock We are offering 9,803,922 shares of our common stock at a price per share of $51.00 pursuant to this prospectus supplement and the accompanying prospectus. Our common stock is listed on the Nasdaq Global Select Market under the t

Calculation of Filing Fee Tables Form 424(b)(5) (Form Type) Cytokinetics, Incorporated (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities

Exhibit 107 Calculation of Filing Fee Tables Form 424(b)(5) (Form Type) Cytokinetics, Incorporated (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation  or Carry Forward Rule Amount Registered(1) Proposed Maximum  Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(2) Carry Forward  Form Type Carry Forward  File Number Carry Forward  Initial Effective Date Filing Fee Previously Paid In Connection  with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Common Stock, par value $0.

Forward-Looking Statements This presentation contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics, Incorporated (“Cytokinetics” or the “Company”) disclaims any intent or ob

Exhibit 99.1 EMPOWERING muscle EMPOWERING lives Forward-Looking Statements This presentation contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics, Incorporated (“Cytokinetics” or the “Company”) disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor

SUBJECT TO COMPLETION, DATED MAY 22, 2024

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-268483 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying pros

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 22, 2024 Cytokinetics, Incorporated (Exact Name of Registrant as Specified in Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission Fil

Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 22, 2024 Cytokinetics, Incorporated (Exact Name of Registrant as Specified in Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission Fil

Cytokinetics, Incorporated Amended and Restated 2015 Employee Stock Purchase Plan

CYTOKINETICS, INCORPORATED 2015 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: FEBRUARY 3, 2015 APPROVED BY THE STOCKHOLDERS: MAY 20, 2015 AMENDED AND RESTATED AND APPROVED BY THE STOCKHOLDERS: May 13, 2020 AMENDED AND RESTATED AND APPROVED BY THE STOCKHOLDERS: May 15, 2024 1.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2024 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission

CYTOKINETICS ANNOUNCES ADDITIONAL RESULTS FROM SEQUOIA-HCM PRESENTED IN LATE BREAKING CLINICAL TRIAL SESSION AT THE EUROPEAN SOCIETY OF CARDIOLOGY HEART FAILURE 2024 CONGRESS Analyses of SEQUOIA-HCM Elaborate on Dosing and Measures of Safety During T

CYTOKINETICS ANNOUNCES ADDITIONAL RESULTS FROM SEQUOIA-HCM PRESENTED IN LATE BREAKING CLINICAL TRIAL SESSION AT THE EUROPEAN SOCIETY OF CARDIOLOGY HEART FAILURE 2024 CONGRESS Analyses of SEQUOIA-HCM Elaborate on Dosing and Measures of Safety During Treatment with Aficamten Results from Cardiopulmonary Exercise Testing Showed Improvement in Exercise Performance were Strongly Correlated to Other Measures of Clinical Improvement Company to Host Investor Event and Webcast Today at 4:00 PM Western European Summer Time (11:00 AM Eastern Time) SOUTH SAN FRANCISCO, Calif.

CYTOKINETICS ANNOUNCES PRIMARY RESULTS FROM SEQUOIA-HCM PRESENTED IN LATE BREAKING CLINICAL TRIAL SESSION AT THE EUROPEAN SOCIETY OF CARDIOLOGY HEART FAILURE 2024 CONGRESS AND PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE Statistically Significant

CYTOKINETICS ANNOUNCES PRIMARY RESULTS FROM SEQUOIA-HCM PRESENTED IN LATE BREAKING CLINICAL TRIAL SESSION AT THE EUROPEAN SOCIETY OF CARDIOLOGY HEART FAILURE 2024 CONGRESS AND PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE Statistically Significant and Clinically Meaningful Improvements Observed in Primary Efficacy Endpoint and All Secondary Endpoints; Results Consistent Across All Prespecified Subgroups Rapid and Sustained Improvements Observed in Symptoms and Function; No Treatment Interruptions Due to Low LVEF Company to Host Investor Event and Webcast Today at 4:00 PM Western European Summer Time (11:00 AM Eastern Time) SOUTH SAN FRANCISCO, Calif.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-50633 CYTOKINET

Form of Performance Stock Unit Award Agreement

Exhibit 10.2 Notice of Grant of Restricted Stock Unit and Award Agreement Cytokinetics Incorporated ID: 94-3291317 350 Oyster Point Blvd. South San Francisco, CA 94080 FIRSTNAME-MIDDLENAME-LASTNAME ADDRESSLINE1 ADDRESSLINE2 CITY, STATE-COUNTRY-ZIPCODE Award Number: Plan: ID: OPTIONNUMBER EQUITYPLAN EMPLOYEEIDENTIFIER Unless otherwise defined herein, the terms defined in the Cytokinetics, Incorpora

Description of Director Compensation

Exhibit 10.1 DESCRIPTION OF DIRECTOR COMPENSATION Our non-employee director compensation program consists of both a cash component and an equity component. Non-employee directors are also able to elect to receive their annual base retainers in equity, as further described below. We do not compensate members of the Board of Directors or committees on a per-meeting basis. Annual Retainers Our non-em

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 08, 2024 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission

CYTOKINETICS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS Primary Results and Two Additional Analyses from SEQUOIA-HCM to be Presented in a Late-Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress Initiat

CYTOKINETICS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS Primary Results and Two Additional Analyses from SEQUOIA-HCM to be Presented in a Late-Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress Initiated Enrollment in CEDAR-HCM, a Clinical Trial of Aficamten in a Pediatric Population with Obstructive HCM Announced Topline Data from the Phase 1 Study of CK-586; Phase 2 Clinical Trial to Begin in Q4 2024 SOUTH SAN FRANCISCO, Calif.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 08, 2024 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 08, 2024 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2024 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commissi

ARS

ANNUAL REPORT 2023 REACHING NEW HEIGHTSResearch Protein Target Myosin-Targeted Therapy Other Biology Troponin- Targeted Therapy Therapeutic Area oHCM $ ȴ FDPWHQ Preparing for regulatory submissions in 2H 2024 EMA review pending $ ȴ FDPWHQ $ ȴ FDPWHQ 2 PHFDPW LY 0HFDUELO CK-136 5 HVHDUFK oHCM (First-line*) nHCM HFpEF HFrEF Heart Failure, other Muscle Biology Directed CK-586 Drug Candidate Pre-Clini

SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

TABLE OF CONTENTS SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under § 240.

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 05, 2024 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 From the transition period from to Commission file number: 000-50633 CYTOKINETICS,

Incentive Compensation Recoupment Policy

EXHIBIT 97.1 Cytokinetics, Incorporated Incentive Compensation Recoupment Policy 1. Introduction The Board of Directors (the “Board”) of Cytokinetics, Incorporated, a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this “Policy”) providing for the Company’s recoupment o

Fifth Amendment to Lease, dated November 27, 2023, by and between the Company and KR Oyster Point 1, LLC

EXHIBIT 10.6 FIFTH AMENDMENT TO LEASE This FIFTH AMENDMENT TO LEASE ("Fifth Amendment") is made and entered into as of November 27, 2023 (the "Effective Date"), by and between KR OYSTER POINT I, LLC, a Delaware limited liability company ("Landlord"), and CYTOKINETICS INCORPORATED, a Delaware corporation ("Tenant"). r e c i t a l s : A. Landlord and Tenant are parties to the Lease dated July 24, 20

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2024 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commi

CYTOKINETICS REPORTS FOURTH QUARTER 2023 FINANCIAL RESULTS Topline Results from SEQUOIA-HCM Announced in December Showed Statistically Significant and Clinically Meaningful Increase in Primary Efficacy Endpoint and Improvements in All Secondary Endpo

CYTOKINETICS REPORTS FOURTH QUARTER 2023 FINANCIAL RESULTS Topline Results from SEQUOIA-HCM Announced in December Showed Statistically Significant and Clinically Meaningful Increase in Primary Efficacy Endpoint and Improvements in All Secondary Endpoints Company Plans to Submit New Drug Application for Aficamten to FDA in Q3 2024 and Marketing Authorization Application to EMA in Q4 2024 Primary Results from SEQUOIA-HCM Are Expected to be Presented at an Upcoming Medical Conference in Q2 2024 Company Provides 2024 Financial Guidance; Approximately 2 Years of Cash Runway SOUTH SAN FRANCISCO, Calif.

CYTK / Cytokinetics, Incorporated / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv0726-cytokineticsinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: Cytokinetics Inc Title of Class of Securities: Common Stock CUSIP Number: 23282W605 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate th

CYTK / Cytokinetics, Incorporated / FMR LLC Passive Investment

SCHEDULE 13G Amendment No.3 CYTOKINETICS INC COMMON STOCK Cusip #23282W605 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #23282W605 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 12,991,435 Item 6: 0 Item 7: 13,007,783 Item 8: 0 Item 9: 13,007,783 Item 11: 13

CYTK / Cytokinetics, Incorporated / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment

SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Cytokinetics, Incorporated (Name of Issuer) Common Stock (Title of Class of Securities) 23282W605 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2024 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commis

CYTK / Cytokinetics, Incorporated / STATE STREET CORP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 AMENDED FILING CYTOKINETICS INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 23282W605 (CUSIP NUMBER) 12/31/2023 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE IS FILED

CYTK / Cytokinetics, Incorporated / BlackRock Inc. Passive Investment

SC 13G/A 1 us23282w6057012224.txt us23282w6057012224.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 5) CYTOKINETICS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 23282W605 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 27, 2023 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commi

Amended and Restated Bylaws.

AMENDED AND RESTATED BYLAWS OF CYTOKINETICS, INCORPORATED (as amended and restated on November 16, 2023) Table of Contents Page Article I CORPORATE OFFICES 1 1.

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2023 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe

CYTOKINETICS REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS On Track for Topline Results from SEQUOIA-HCM a Pivotal Phase 3 Clinical Trial of Aficamten in Obstructive HCM, in Late December Long-Term Data from FOREST-HCM, the Open-Label Extension Study

CYTOKINETICS REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS On Track for Topline Results from SEQUOIA-HCM a Pivotal Phase 3 Clinical Trial of Aficamten in Obstructive HCM, in Late December Long-Term Data from FOREST-HCM, the Open-Label Extension Study of Aficamten, Show Sustained Improvements in Clinical Efficacy Endpoints and No Treatment Interruptions for Low Ejection Fraction Initiated Enrollment in ACACIA-HCM, a Pivotal Phase 3 Clinical Trial of Aficamten in Non-Obstructive HCM SOUTH SAN FRANCISCO, Calif.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 02, 2023 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commi

©2023 CYTOKINETICS, All Rights Reserved. CYTOKINETICS® and the C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

©2023 CYTOKINETICS, All Rights Reserved. CYTOKINETICS® and the C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries. Forward-Looking Statements This Presentation contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looki

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 19, 2023 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commis

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 06, 2023 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commis

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2023 Cytokinetics, Incorporated (Exact name of Registrant as specified in its charter) Delaware 000-50633 94-3291317 (State or other jurisdiction of incorporation or org

Cytokinetics, Incorporated Executive Severance Plan and Summary Plan Description

Exhibit 10.1 CYTOKINETICS, INCORPORATED EXECUTIVE SEVERANCE PLAN AND SUMMARY PLAN DESCRIPTION (Adopted by the Compensation and Talent Committee on September 26, 2023) 1. Introduction. The purpose of this Cytokinetics, Incorporated Executive Severance Plan (the “Plan”) is to provide assurances of specified severance benefits to eligible employees of the Company whose employment is involuntarily ter

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 03, 2023 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commiss

CYTOKINETICS REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS Completed Enrollment in SEQUOIA-HCM, Pivotal Phase 3 Trial of Aficamten in Obstructive HCM; On Track for Topline Results by the End of the Year Initiated Enrollment in MAPLE-HCM, a Phase 3 Cl

CYTOKINETICS REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS Completed Enrollment in SEQUOIA-HCM, Pivotal Phase 3 Trial of Aficamten in Obstructive HCM; On Track for Topline Results by the End of the Year Initiated Enrollment in MAPLE-HCM, a Phase 3 Clinical Trial Comparing Aficamten and Metoprolol in Obstructive HCM ACACIA-HCM, a Pivotal Phase 3 Clinical Trial of Aficamten in Non-Obstructive HCM, Expected to Start in September 2023 Company Reduces Projected Spending by Approximately 15% and Revises 2023 Financial Spending Guidance SOUTH SAN FRANCISCO, Calif.

Certificate of Amendment of Amended and Restated Certificate of Incorporation

EXHIBIT 3.5 CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CYTOKINETICS, INCORPORATED CYTOKINETICS, INCORPORATED, a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies that: FIRST: The name of the corporation is CYTOKINETICS, INCORPORATED. SECOND: The date on which the Ce

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00

CYTOKINETICS PRESENTS NEW DATA IN PATIENTS WITH NON-OBSTRUCTIVE HCM FROM COHORT 4 OF REDWOOD-HCM IN LATE-BREAKING CLINICAL TRIAL SESSION AT THE EUROPEAN SOCIETY OF CARDIOLOGY HEART FAILURE 2023 CONGRESS Treatment of Aficamten was Well-Tolerated and A

CYTOKINETICS PRESENTS NEW DATA IN PATIENTS WITH NON-OBSTRUCTIVE HCM FROM COHORT 4 OF REDWOOD-HCM IN LATE-BREAKING CLINICAL TRIAL SESSION AT THE EUROPEAN SOCIETY OF CARDIOLOGY HEART FAILURE 2023 CONGRESS Treatment of Aficamten was Well-Tolerated and Associated with Statistically Significant Improvements in KCCQ, Angina Frequency, NYHA Class, NTpro-BNP and High-Sensitivity Troponin I Phase 3 Clinical Trial in Non-Obstructive HCM To Begin in 2H 2023 SOUTH SAN FRANCISCO, Calif.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2023 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 04, 2023 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission

CYTOKINETICS REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS SEQUOIA-HCM Nearing Completion of Enrollment; On Track for Results in Q4 2023 Additional Data from Cohort 4 of REDWOOD-HCM to be Presented in Late-Breaking Clinical Trial Session at European S

CYTOKINETICS REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS SEQUOIA-HCM Nearing Completion of Enrollment; On Track for Results in Q4 2023 Additional Data from Cohort 4 of REDWOOD-HCM to be Presented in Late-Breaking Clinical Trial Session at European Society of Cardiology Heart Failure 2023 Congress Company to Reduce Spending by More Than 10% in 2023 to Maintain Over 2 Years of Cash Runway SOUTH SAN FRANCISCO, Calif.

ARS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 From the transition period from to Commission file number: 000-50633 CYTOKINETICS,

SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to § 240.

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2023 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commissi

SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to § 240.

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 04, 2023 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 From the transition period from to Commission file number: 000-50633 CYTOKINETICS,

Calculation of Filing Fee Tables (Form Type) Cytokinetics, Incorporated (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward

Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Cytokinetics, Incorporated (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee Newly Registered Securities Fees to Be Paid Equity Common stock, par value $0.

$300,000,000 Common Stock

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-268483 PROSPECTUS SUPPLEMENT (To Prospectus dated November 18, 2022) $300,000,000 Common Stock We have entered into an amended and restated Controlled Equity OfferingSM Sales Agreement with Cantor Fitzgerald & Co., dated March 1, 2023. In accordance with the terms of the Amended and Restated Controlled Equity OfferingSM

Fourth Amendment to Lease, dated October 12, 2022, by and between the Company and KR Oyster Point 1, LLC

Exhibit 10.5 FOURTH AMENDMENT TO LEASE This FOURTH AMENDMENT TO LEASE ("Fourth Amendment") is made and entered into as of October 12, 2022, by and between KR OYSTER POINT I, LLC, a Delaware limited liability company ("Landlord"), and CYTOKINETICS INCORPORATED, a Delaware corporation ("Tenant"). r e c i t a l s : A. Landlord and Tenant are parties to the Lease dated July 24, 2019 (the "Original Lea

Form of Restricted Stock Unit Award Agreement (Employee Annual Grant)

Exhibit 10.15 Notice of Grant of Restricted Stock Unit and Award Agreement Cytokinetics Incorporated ID: 94-3291317 350 Oyster Point Blvd. South San Francisco, CA 94080 First and Last Name Address line 1 Address line 2 City, State and Zip Code Unless otherwise defined herein, the terms defined in the Cytokinetics, Incorporated Amended and Restated 2004 Equity Incentive Plan (the “Plan”) shall have

Form of Option Agreement (New Hire Inducement)

Exhibit 10.12 Notice of Grant of Stock Options and Option Agreement Cytokinetics Incorporated ID: 94-3291317 350 Oyster Point Boulevard South San Francisco, CA 94080 First and Last Name Address Line 1 Address Line 2 City, State and Zip Code Unless otherwise defined herein, the terms defined in the Cytokinetics, Incorporated Amended and Restated 2004 Equity Incentive Plan (the “Plan”) shall have th

Form of Option Agreement (Director Onboarding)

Exhibit 10.14 Notice of Grant of Stock Options and Award Agreement Cytokinetics Incorporated ID: 94-3291317 350 Oyster Point Boulevard South San Francisco, CA 94080 First and Last Name Address Line 1 Address Line 2 City, State, Zip Code Unless otherwise defined herein, the terms defined in the Cytokinetics, Incorporated Amended and Restated 2004 Equity Incentive Plan (the “Plan”) shall have the sa

CYTOKINETICS REPORTS FOURTH QUARTER 2022 FINANCIAL RESULTS Company Received Complete Response Letter from FDA for New Drug Application for Omecamtiv Mecarbil Data from Cohort 4 of REDWOOD-HCM to be Presented at the American College of Cardiology Scie

CYTOKINETICS REPORTS FOURTH QUARTER 2022 FINANCIAL RESULTS Company Received Complete Response Letter from FDA for New Drug Application for Omecamtiv Mecarbil Data from Cohort 4 of REDWOOD-HCM to be Presented at the American College of Cardiology Scientific Sessions; Results Expected from SEQUOIA-HCM in Q4 2023 Second Interim Analysis of COURAGE-ALS Expected to Occur in Q2 2023 Company Provides 2023 Financial Guidance; More than 2 Years of Cash Runway SOUTH SAN FRANCISCO, Calif.

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) CYTOKINETICS, INCORPORATED (Exact name of Registrant as specified in its charter) Table 1: Newly Registered Securities Security Type Title of Securities to be Registered Fee Calculation Rule Amount to be Registered(1) Proposed Maximum Offering Price Per Share Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock $0.

Second Amendment to Development Funding Loan Agreement, dated December 8, 2022, by and among Royalty Pharma Development Funding, LLC and the Company

Exhibit 10.23 SECOND AMENDMENT This SECOND AMENDMENT (this “Amendment”), effective as of December 8, 2022, is executed by and between ROYALTY PHARMA DEVELOPMENT FUNDING, LLC, a Delaware limited liability company (“RP” and the “Lender” and together with RP’s affiliates, successors and/or assignees that become Lenders hereunder, collectively but not jointly, the “Lenders”) and CYTOKINETICS, INCORPOR

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 01, 2023 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commissi

Form of Option Agreement (Employee Annual Grant)

Exhibit 10.11 Notice of Grant of Stock Options and Award Agreement Cytokinetics Incorporated ID: 94-3291317 350 Oyster Point Boulevard South San Francisco, CA 94080 First and Last Name Address Line 1 Address Line 2 City, State and Zip Code Unless otherwise defined herein, the terms defined in the Cytokinetics, Incorporated Amended and Restated 2004 Equity Incentive Plan (the “Plan”) shall have the

Form of Option Agreement (Director Annual Grant)

Exhibit 10.13 Notice of Grant of Stock Options and Award Agreement Cytokinetics Incorporated ID: 94-3291317 350 Oyster Point Boulevard South San Francisco, CA 94080 First and Last Name Address Line 1 Address Line 2 City, State and Zip Code Unless otherwise defined herein, the terms defined in the Cytokinetics, Incorporated Amended and Restated 2004 Equity Incentive Plan (the “Plan”) shall have the

First Amendment to Development Funding Loan Agreement, dated July 6, 2022, by and among Royalty Pharma Development Funding, LLC and the Company

Exhibit 10.22 CONSENT AND AMENDMENT This CONSENT AND AMENDMENT (this “Amendment”), effective as of June 30, 2022, is executed by and between ROYALTY PHARMA DEVELOPMENT FUNDING, LLC, a Delaware limited liability company (“RP” and the “Lender” and together with RP’s affiliates, successors and/or assignees that become Lenders hereunder, collectively but not jointly, the “Lenders”) and CYTOKINETICS, I

As filed with the Securities and Exchange Commission on March 1, 2023

As filed with the Securities and Exchange Commission on March 1, 2023 Registration No.

Certificate of Change of Registered Agent

Exhibit 4.9 STATE OF DELAWARE CERTIFICATE OF CHANGE OF REGISTERED AGENT AND/OR REGISTERED OFFICE The corporation organized and existing under the General Corporation Law of the State of Delaware hereby certifies as follows: 1. The name of the corporation is CYTOKINETICS, INCORPORATED 2. The Registered Office of the corporation in the State of Delaware is changed to 251 Little Falls Drive (street),

Amended and Restated Controlled Equity Offering Sales Agreement, dated as of March 1, 2023, by and between the Company and Cantor Fitzgerald & Co.

Exhibit 10.28 Cytokinetics, Incorporated Shares of Common Stock (par value $0.001 per share) Amended and Restated Controlled Equity OfferingSM Sales Agreement March 1, 2023 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: Cytokinetics, Incorporated, a Delaware corporation (the “Company”), confirms its amended and restated agreement (this “Agreement”) with Cantor Fit

Amended and Restated 2004 Equity Incentive Plan

Exhibit 10.9 CYTOKINETICS, INCORPORATED AMENDED AND RESTATED 2004 EQUITY INCENTIVE PLAN AMENDED BY THE BOARD OF DIRECTORS: FEBRUARY 6, 2013 APPROVED BY STOCKHOLDERS: MAY 22, 2013 AMENDED TO REFLECT THE REVERSE STOCK SPLIT: JUNE 25, 2013 AMENDED AND RESTATED BY THE BOARD OF DIRECTORS: FEBRUARY 3, 2015 APPROVED BY STOCKHOLDERS: MAY 20, 2015 AMENDED AND RESTATED BY THE BOARD OF DIRECTORS: FEBRUARY 10

Form of Restricted Stock Unit Award Agreement (Employee Key Performer)

Exhibit 10.16 Notice of Grant of Restricted Stock Unit and Award Agreement Cytokinetics Incorporated ID: 94-3291317 350 Oyster Point Blvd. South San Francisco, CA 94080 First and Last Name Address Line 1 Address Line 2 City, State and Zip Code Unless otherwise defined herein, the terms defined in the Cytokinetics, Incorporated Amended and Restated 2004 Equity Incentive Plan (the “Plan”) shall have

Description of Securities

Exhibit 4.6 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Cytokinetics, Incorporated (“we,” “our,” or “us,”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our common stock, $0.001 par value per share (the “Common Stock”). The following summary set

Form of Restricted Stock Unit Award Agreement (Director Annual Grant)

Exhibit 10.17 Notice of Grant of Restricted Stock Unit and Award Agreement Cytokinetics Incorporated ID: 94-3291317 350 Oyster Point Blvd. South San Francisco, CA 94080 First and Last Name Address Line 1 Address Line 2 City, State and Zip Code Unless otherwise defined herein, the terms defined in the Cytokinetics, Incorporated Amended and Restated 2004 Equity Incentive Plan (the “Plan”) shall have

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2023 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commi

Compensation Information for the Company’s Named Executive Officers

Compensation Information for the Company’s Named Executive Officers Robert I. Blum, President & Chief Executive Officer: · 2023 base salary $790,000; · 2022 bonus award $395,705; and · 2023 target bonus is 75% of base salary. Ching W. Jaw, Senior Vice President, Finance and Chief Financial Officer: · 2023 base salary $525,971; · 2022 bonus award $193,145; and · 2023 target bonus is 45% of base sal

Amended and Restated Bylaws

AMENDED AND RESTATED BYLAWS OF CYTOKINETICS, INCORPORATED (as amended and restated on February 14, 2023) 280969645 v2 Table of Contents Page Article I CORPORATE OFFICES 1 1.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2023 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commi

CYTK / Cytokinetics, Inc. / BlackRock Inc. Passive Investment

SC 13G/A 1 us23282w6057021023.txt us23282w6057021023.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 4) CYTOKINETICS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 23282W605 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box t

CYTK / Cytokinetics, Inc. / FMR LLC Passive Investment

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.2 CYTOKINETICS INC COMMON STOCK Cusip #23282W605 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #23282W605 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 13,406,654 Item 6: 0 Item 7: 13,409,243 Item 8: 0 Item 9:

CYTK / Cytokinetics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: Cytokinetics Inc. Title of Class of Securities: Common Stock CUSIP Number: 23282W605 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ R

CYTK / Cytokinetics, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Cytokinetics, Incorporated (Name of Issuer) Common Stock (Title of Class of Securities) 23282W605 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th

CYTK / Cytokinetics, Inc. / STATE STREET CORP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 AMENDED FILING CYTOKINETICS INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 23282W605 (CUSIP NUMBER) 12/31/2022 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE IS FILED

CYTK / Cytokinetics, Inc. / BlackRock Inc. Passive Investment

SC 13G/A 1 us23282w6057012623.txt us23282w6057012623.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 3) CYTOKINETICS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 23282W605 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box t

CYTK / Cytokinetics, Inc. / BlackRock Inc. Passive Investment

us23282w6057012023.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 2) CYTOKINETICS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 23282W605 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w

Forward-Looking Statements This Presentation contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking stateme

EX-99.1 2 cytk-ex991.htm EX-99.1 Forward-Looking Statements This Presentation contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements in

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 09, 2023 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commis

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2022 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commi

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 08, 2022 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commi

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 08, 2022 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commi

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 07, 2022 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commi

Filing Fee Table

EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Cytokinetics, Incorporated (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate(4) Amount of Registration Fee(4) Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Common Stock, $0.

As filed with the Securities and Exchange Commission on November 18, 2022

S-3ASR Table of Contents As filed with the Securities and Exchange Commission on November 18, 2022 Registration No.

Form of Preferred Stock Warrant Agreement and Warrant Certificate.

EX-4.11 Exhibit 4.11 CYTOKINETICS, INCORPORATED AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF CYTOKINETICS, INCORPORATED FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between CYTOKINETICS, INCORPORATED, a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association

Form of Debt Securities Warrant Agreement and Warrant Certificate.

Exhibit 4.12 CYTOKINETICS, INCORPORATED AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF CYTOKINETICS, INCORPORATED FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between CYTOKINETICS, INCORPORATED, a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organi

Form of Common Stock Warrant Agreement and Warrant Certificate.

EX-4.10 Exhibit 4.10 CYTOKINETICS, INCORPORATED AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF CYTOKINETICS, INCORPORATED FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between CYTOKINETICS, INCORPORATED, a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organiz

Form of Indenture.

EX-4.8 Exhibit 4.8 CYTOKINETICS, INCORPORATED AND , AS TRUSTEE FORM OF INDENTURE DATED AS OF Debt Securities CYTOKINETICS, INCORPORATED FORM OF INDENTURE THIS INDENTURE, dated as of [•], between CYTOKINETICS, INCORPORATED, a Delaware corporation (the “Company”), and [TRUSTEE], as trustee (the “Trustee”): WHEREAS, for its lawful corporate purposes, the Company has duly authorized the execution and

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 07, 2022 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe

Description of Director Compensation

Exhibit 10.1 DESCRIPTION OF DIRECTOR COMPENSATION Our non-employee director compensation program consists of both a cash component and an equity component. Non-employee directors are also able to elect to receive their annual base retainers in equity, as further described below. We do not compensate members of the Board of Directors or committees on a per-meeting basis. Annual Retainers Our non-em

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 03, 2022 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commi

CYTOKINETICS REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS Advisory Committee Meeting to Review NDA for Omecamtiv Mecarbil on December 13, 2022; PDUFA Target Action Date Set for February 28, 2023 SEQUOIA-HCM Continuing with Results Expected in 2H 2023

CYTOKINETICS REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS Advisory Committee Meeting to Review NDA for Omecamtiv Mecarbil on December 13, 2022; PDUFA Target Action Date Set for February 28, 2023 SEQUOIA-HCM Continuing with Results Expected in 2H 2023; Patient Screening for Cohort 4 of REDWOOD-HCM Closed with Data Expected in 1H 2023 COURAGE-ALS Continuing Following First Interim Analysis, Enrollment Expected to Complete in 1H 2023 SOUTH SAN FRANCISCO, Calif.

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2022 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commis

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 02, 2022 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commis

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2022 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Comm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 04, 2022 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commiss

CYTOKINETICS REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS Advisory Committee Meeting to Review NDA for Omecamtiv Mecarbil Scheduled for December 13, 2022; PDUFA Target Action Date Set for February 28, 2023 Company Revises 2022 Financial Guidance; Re

CYTOKINETICS REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS Advisory Committee Meeting to Review NDA for Omecamtiv Mecarbil Scheduled for December 13, 2022; PDUFA Target Action Date Set for February 28, 2023 Company Revises 2022 Financial Guidance; Reduces Projected Spending for 2022 SOUTH SAN FRANCISCO, Calif.

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 04, 2022 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commiss

CYTOKINETICS ANNOUNCES PRICING OF $450 MILLION CONVERTIBLE SENIOR NOTES OFFERING

Exhibit 99.2 CYTOKINETICS ANNOUNCES PRICING OF $450 MILLION CONVERTIBLE SENIOR NOTES OFFERING SOUTH SAN FRANCISCO, Calif., July 01, 2022 (GLOBE NEWSWIRE) ? Cytokinetics, Incorporated (?Cytokinetics?) (Nasdaq: CYTK) today announced the pricing of its offering of $450.0 million aggregate principal amount of 3.50% convertible senior notes due 2027 (the ?notes?) in a private offering to qualified inst

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): June 30, 2022 Cytokinetics, Incorporated (Exact Name of Registrant as Specified in Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission Fi

CYTOKINETICS ANNOUNCES PROPOSED CONVERTIBLE SENIOR NOTES OFFERING

Exhibit 99.1 CYTOKINETICS ANNOUNCES PROPOSED CONVERTIBLE SENIOR NOTES OFFERING SOUTH SAN FRANCISCO, Calif., June 29, 2022 (GLOBE NEWSWIRE) ? Cytokinetics, Incorporated (?Cytokinetics?) (Nasdaq: CYTK) today announced its intention to offer, subject to market and other conditions, $450.0 million aggregate principal amount of convertible senior notes due 2027 (the ?notes?) in a private offering to qu

Indenture, dated July 6, 2022, between the Company and U.S. Bank Trust Company, National Association, as Trustee (including the form of 3.50% Convertible Senior Notes due 2027)

Exhibit 4.1 EXECUTION VERSION CYTOKINETICS, INCORPORATED and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION as Trustee INDENTURE Dated as of July 6, 2022 3.50% Convertible Senior Notes due 2027 TABLE OF CONTENTS Page Article 1. Definitions; Rules of Construction 1 Section 1.01. Definitions 1 Section 1.02. Other Definitions 13 Section 1.03. Rules of Construction 14 Article 2. The Notes 15 Section 2.

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): June 24, 2022 Cytokinetics, Incorporated (Exact Name of Registrant as Specified in Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission Fi

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): June 15, 2022 Cytokinetics, Incorporated (Exact Name of Registrant as Specified in Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission Fi

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): June 16, 2022 Cytokinetics, Incorporated (Exact Name of Registrant as Specified in Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission Fi

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): June 13, 2022 Cytokinetics, Incorporated (Exact Name of Registrant as Specified in Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission Fi

Amended and Restated 2004 Equity Incentive Plan.

Exhibit 99.1 CYTOKINETICS, INCORPORATED AMENDED AND RESTATED 2004 EQUITY INCENTIVE PLAN AMENDED BY THE BOARD OF DIRECTORS: FEBRUARY 6, 2013 APPROVED BY STOCKHOLDERS: MAY 22, 2013 AMENDED TO REFLECT THE REVERSE STOCK SPLIT: JUNE 25, 2013 AMENDED AND RESTATED BY THE BOARD OF DIRECTORS: FEBRUARY 3, 2015 APPROVED BY STOCKHOLDERS: MAY 20, 2015 AMENDED AND RESTATED BY THE BOARD OF DIRECTORS: FEBRUARY 10

As filed with the Securities and Exchange Commission on May 31, 2022

As filed with the Securities and Exchange Commission on May 31, 2022 Registration No.

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) CYTOKINETICS, INCORPORATED (Exact name of Registrant as specified in its charter) Table 1: Newly Registered Securities Security Type Title of Securities to be Registered Fee Calculation Rule Amount to be Registered(1) Proposed Maximum Offering Price Per Share Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock $ 0.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2022 Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 23, 2022 Cytokinetics, Incorporated (Exact Name of Registrant as Specified in Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission Fil

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 18, 2022 Cytokinetics, Incorporated (Exact Name of Registrant as Specified in Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission Fil

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 17, 2022 Cytokinetics, Incorporated (Exact Name of Registrant as Specified in Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission Fil

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 10, 2022 Cytokinetics, Incorporated (Exact Name of Registrant as Specified in Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0

Cytokinetics Reports First Quarter 2022 Financial Results Initial Data from REDWOOD-HCM OLE, the Open Label Extension Study of Aficamten, to be Presented at Heart Failure 2022 on May 23, 2022 Continued Launch Readiness Activities and Buildout of Comm

EXHIBIT 99.1 Cytokinetics Reports First Quarter 2022 Financial Results Initial Data from REDWOOD-HCM OLE, the Open Label Extension Study of Aficamten, to be Presented at Heart Failure 2022 on May 23, 2022 Continued Launch Readiness Activities and Buildout of Commercial Infrastructure in Advance of PDUFA Date of November 30, 2022 for Omecamtiv Mecarbil SOUTH SAN FRANCISCO, Calif., May 04, 2022 (GLO

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2022 Cytokinetics, Incorporated (Exact name of registrant as specified in its charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): April 12, 2022 Cytokinetics, Incorporated (Exact Name of Registrant as Specified in Charter) Delaware 000-50633 94-3291317 (State or Other Jurisdiction of Incorporation) (Commission F

SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definitive Additional Materials ? Soliciting Material Pursuant to ? 240.

CYTK / Cytokinetics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: Cytokinetics Inc. Title of Class of Securities: Common Stock CUSIP Number: 23282W605 Date of Event Which Requires Filing of this Statement: March 31, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule